Skip to main content
LIFECORE BIOMEDICAL, INC. \DE\ logo

LIFECORE BIOMEDICAL, INC. \DE\ — Investor Relations & Filings

Ticker · LFCR ISIN · US5147661046 LEI · 549300EHBZ5OM9ND9O43 US Manufacturing
Open in API
Filings indexed 1,096 across all filing types
Latest filing 2020-07-27 Director's Dealing
Country US United States of America
Listing US LFCR

About LIFECORE BIOMEDICAL, INC. \DE\

https://www.lifecore.com/

Lifecore Biomedical is an integrated contract development and manufacturing organization (CDMO) that specializes in sterile injectable pharmaceutical drug products and medical devices. The company provides a full range of services, including specialty formulation, process development, aseptic filling, and final packaging, supporting products from clinical phases through to commercial supply. A key area of expertise is the handling of complex and highly viscous formulations. In addition to its CDMO capabilities, Lifecore is a primary producer of non-animal-sourced sodium hyaluronate (hyaluronic acid), offering it in various molecular weights and formats, including bulk material, hydrogels, and filled syringes and vials for diverse applications.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2020-07-27 English
PRIMARY DOCUMENT
Director's Dealing
2020-07-27 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Landec Corporation. It details the entry into a material definitive agreement, specifically the Limited Waiver and Eighth Amendment to the Credit Agreement, including financial terms and fees paid. The document is not a full financial report but an update on financing activities and amendments to credit terms. It includes detailed information about the credit facility amendment, interest rates, and financial covenants, which aligns with updates on company financing activities. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is 7,670 characters, which is substantive and contains detailed information rather than a brief announcement or certification. Hence, it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA).
2020-07-16 English
SC 13G/A
Major Shareholding Notification
2020-07-10 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 29, 2020, by Landec Corporation. It announces preliminary financial results for the fiscal fourth quarter ended May 31, 2020, and provides operational updates including a business transformation initiative and credit agreement status. The document includes a press release with unaudited preliminary financial data and a conference call announcement. It is not a full annual or quarterly report but a current report disclosing material events and preliminary financial results. The presence of preliminary financial results and operational updates in a Form 8-K aligns with the category of Earnings Release (ER), which covers initial announcements of quarterly or periodical financial results with key highlights. The document is lengthy (15,000 characters) and contains substantive financial data, not merely a notice or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Therefore, the best classification is Earnings Release (ER).
2020-06-29 English
SC 13D/A
Major Shareholding Notification
2020-06-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.